FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135903479> ?p ?o ?g. }

• W2135903479 endingPage "1001" @default.
• W2135903479 startingPage "1001" @default.
• W2135903479 abstract "The short-term safety and efficacy of zoledronic acid for the treatment of skeletal metastasis was evaluated in patients with hormone-refractory prostate cancer.A total of 19 hormone-refractory prostate cancer patients with bone metastases were enrolled. All patients received up to six infusions of zoledronic acid (4 mg, given intravenously over 15 minutes, every 3-4 weeks). Safety was assessed by monitoring adverse events and serum creatinine levels. Efficacy was assessed by monitoring skeletal-related events, brief pain inventory score, quality of life score, type of pain medication, and analgesic score. Mean age of patients was 67.3 years (46-86 years), mean time from diagnosis of bone metastases was 27.6 months (0-117 months), and mean time from diagnosis of hormone-refractory disease was 7.5 months (0-26 months).There was no clinically significant change in serum creatinine levels. Eleven adverse events (musculoskeletal disorders and systemic disorders) in 8 patients were classed as having a possible relationship to study drug. Fifteen patients completed six courses of zoledronic acid infusion. There were no significant changes in the brief pain inventory composite scores, quality of life questionnaire scores or analgesic score. No new skeletal-related events developed during the treatment period.Zoledronic acid administered in this study as a 15-minute infusion demonstrated an acceptable and well-known safety profile in patients with refractory prostate cancer with bone metastases. However, prospective placebo- controlled clinical trials are required to elucidate the efficacy of zoledronic acid." @default.
• W2135903479 created "2016-06-24" @default.
• W2135903479 creator A5019918659 @default.
• W2135903479 creator A5030579517 @default.
• W2135903479 creator A5045730291 @default.
• W2135903479 creator A5052570003 @default.
• W2135903479 creator A5065146391 @default.
• W2135903479 creator A5079540101 @default.
• W2135903479 date "2007-01-01" @default.
• W2135903479 modified "2023-09-25" @default.
• W2135903479 title "A Prospective, Multicenter, Open-label Trial of Zoledronic Acid in Patients with Hormone Refractory Prostate Cancer" @default.
• W2135903479 cites W1971660671 @default.
• W2135903479 cites W2001372146 @default.
• W2135903479 cites W2004672175 @default.
• W2135903479 cites W2010219393 @default.
• W2135903479 cites W2015346411 @default.
• W2135903479 cites W2035837990 @default.
• W2135903479 cites W2066553392 @default.
• W2135903479 cites W2066969766 @default.
• W2135903479 cites W2076769374 @default.
• W2135903479 cites W2087324367 @default.
• W2135903479 cites W2104923745 @default.
• W2135903479 cites W2105258029 @default.
• W2135903479 cites W2109333569 @default.
• W2135903479 cites W2111536069 @default.
• W2135903479 cites W2116271944 @default.
• W2135903479 cites W2119509302 @default.
• W2135903479 cites W2125502545 @default.
• W2135903479 cites W2125967305 @default.
• W2135903479 cites W2146306121 @default.
• W2135903479 cites W2161962336 @default.
• W2135903479 cites W2162243202 @default.
• W2135903479 cites W2320909684 @default.
• W2135903479 cites W2607028219 @default.
• W2135903479 cites W3205206586 @default.
• W2135903479 cites W4252639760 @default.
• W2135903479 cites W96430321 @default.
• W2135903479 doi "https://doi.org/10.3349/ymj.2007.48.6.1001" @default.
• W2135903479 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2628173" @default.
• W2135903479 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18159593" @default.
• W2135903479 hasPublicationYear "2007" @default.
• W2135903479 type Work @default.
• W2135903479 sameAs 2135903479 @default.
• W2135903479 citedByCount "4" @default.
• W2135903479 countsByYear W21359034792012 @default.
• W2135903479 countsByYear W21359034792015 @default.
• W2135903479 crossrefType "journal-article" @default.
• W2135903479 hasAuthorship W2135903479A5019918659 @default.
• W2135903479 hasAuthorship W2135903479A5030579517 @default.
• W2135903479 hasAuthorship W2135903479A5045730291 @default.
• W2135903479 hasAuthorship W2135903479A5052570003 @default.
• W2135903479 hasAuthorship W2135903479A5065146391 @default.
• W2135903479 hasAuthorship W2135903479A5079540101 @default.
• W2135903479 hasBestOaLocation W21359034791 @default.
• W2135903479 hasConcept C121332964 @default.
• W2135903479 hasConcept C121608353 @default.
• W2135903479 hasConcept C126322002 @default.
• W2135903479 hasConcept C126894567 @default.
• W2135903479 hasConcept C141071460 @default.
• W2135903479 hasConcept C142424586 @default.
• W2135903479 hasConcept C197934379 @default.
• W2135903479 hasConcept C2776139714 @default.
• W2135903479 hasConcept C2776326535 @default.
• W2135903479 hasConcept C2780192828 @default.
• W2135903479 hasConcept C2780306776 @default.
• W2135903479 hasConcept C71924100 @default.
• W2135903479 hasConcept C87355193 @default.
• W2135903479 hasConceptScore W2135903479C121332964 @default.
• W2135903479 hasConceptScore W2135903479C121608353 @default.
• W2135903479 hasConceptScore W2135903479C126322002 @default.
• W2135903479 hasConceptScore W2135903479C126894567 @default.
• W2135903479 hasConceptScore W2135903479C141071460 @default.
• W2135903479 hasConceptScore W2135903479C142424586 @default.
• W2135903479 hasConceptScore W2135903479C197934379 @default.
• W2135903479 hasConceptScore W2135903479C2776139714 @default.
• W2135903479 hasConceptScore W2135903479C2776326535 @default.
• W2135903479 hasConceptScore W2135903479C2780192828 @default.
• W2135903479 hasConceptScore W2135903479C2780306776 @default.
• W2135903479 hasConceptScore W2135903479C71924100 @default.
• W2135903479 hasConceptScore W2135903479C87355193 @default.
• W2135903479 hasIssue "6" @default.
• W2135903479 hasLocation W21359034791 @default.
• W2135903479 hasLocation W21359034792 @default.
• W2135903479 hasLocation W21359034793 @default.
• W2135903479 hasLocation W21359034794 @default.
• W2135903479 hasOpenAccess W2135903479 @default.
• W2135903479 hasPrimaryLocation W21359034791 @default.
• W2135903479 hasRelatedWork W2042275235 @default.
• W2135903479 hasRelatedWork W2187571762 @default.
• W2135903479 hasRelatedWork W2379841764 @default.
• W2135903479 hasRelatedWork W2390909644 @default.
• W2135903479 hasRelatedWork W2528057197 @default.
• W2135903479 hasRelatedWork W2999797179 @default.
• W2135903479 hasRelatedWork W3032254165 @default.
• W2135903479 hasRelatedWork W2476724097 @default.
• W2135903479 hasRelatedWork W2508119633 @default.
• W2135903479 hasRelatedWork W2780491316 @default.
• W2135903479 hasVolume "48" @default.

• next